This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2014 following the close of market on Tuesday, February 4, 2014.
The Company also will host a conference call on Tuesday, February 4, 2014 at 4:30 p.m. ET to discuss the financial results. Participating on the call will be Peter Meldrum, President and Chief Executive Officer; Mark Capone, President of Myriad Genetic Laboratories, Inc.; and James Evans, Chief Financial Officer.
To listen to the call, interested parties within the United States may dial 800-891-8357 or +1 212-231-2921 for international callers. All callers will be asked to reference reservation number 21703449.
The conference call also will be available through a live webcast at
www.myriad.com . A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21703449.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference inpatients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, myPath Melanoma™, myPlan Lung Cancer™, myRisk Hereditary Cancer™, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
CONTACT: Media Contact: